Charlotte's Web Holdings, Inc. (TSX:CWEB)
Canada · Delayed Price · Currency is CAD | Market Cap | 142.91M +595.7% |
| Revenue (ttm) | 68.41M +0.5% |
| Net Income | -40.78M |
| EPS | -0.26 |
| Shares Out | 160.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87,146 |
| Average Volume | 212,272 |
| Open | 0.8400 |
| Previous Close | 0.8900 |
| Day's Range | 0.8100 - 0.8800 |
| 52-Week Range | 0.1050 - 1.3300 |
| Beta | 2.32 |
| RSI | 46.47 |
| Earnings Date | Mar 31, 2026 |
About Charlotte's Web Holdings
Charlotte's Web Holdings, Inc. engages in the farming, manufacturing, marketing, and sale of hemp-derived cannabidiol (CBD) and other botanical-based wellness products. Its product categories include full-spectrum hemp extract oil tinctures, such as liquid products; gummies; capsules; soft-gels; CBD topical creams and lotions; broad-spectrum botanical CBD; functional mushrooms; and pet products under the Charlotte’s Web, CBD CLINIC, and CBD MEDIC brand names. The company’s products contain naturally occurring phytocannabinoids, including CBD, c... [Read more]
Full Company ProfileFinancial Performance
In 2025, Charlotte's Web Holdings's revenue was $49.90 million, an increase of 0.46% compared to the previous year's $49.67 million. Losses were -$29.74 million, -0.35% less than in 2024.
Financial numbers in USD Financial StatementsNews
CURED Nutrition Joins One Hemp, Strengthening Industry Alignment Ahead of Key Federal Legislative Deadline
CURED Nutrition joins the coalition leading the push for federal hemp regulation and consumer protection Washington, D.C.--(Newsfile Corp. - April 13, 2026) - CURED Nutrition , a Colorado-based wellne...
Charlotte's Web Holdings Earnings Call Transcript: Q4 2025
Q4 2025 saw revenue rebound and cost reductions, with a transformative BAT transaction eliminating debt and adding capital. Positioned for growth via Medicare pilots and regulatory momentum, but faces ongoing federal uncertainty.
Charlotte's Web Reports 2025 Fourth Quarter and Full Year Financial Results
Anticipated CMMI Medicare Pilot Program Participation, Regulatory Momentum, and Cost Structure Improvements Position Company for Growth and Pathway to Profitability LOUISVILLE, Colo., March 31, 2026 /...
Charlotte's Web Announces Transaction with BAT: Debenture Conversion and US$10M Equity Investment to Strengthen Balance Sheet
Transaction Addresses Capital Structure and Supports Near-Term Operating Priorities, Including Anticipated CMMI Medicare Pilot Program Participation LOUISVILLE, Colo., March 30, 2026 /PRNewswire/ - (T...
Charlotte's Web 2025 Fourth Quarter and Year-End Earnings Call and Webcast Notice
LOUISVILLE, Colo., March 24, 2026 /PRNewswire/ - (TSX: CWEB) (OTC: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") a botanical wellness innovation company and the market lea...
Charlotte's Web Welcomes New CMS Guidance, Advancing Access to Eligible Full‑Spectrum Hemp Products
LOUISVILLE, Colo., March 20, 2026 /PRNewswire/ - (TSX: CWEB) (OTCQB: CWBHF) Charlotte's Web Holdings, Inc. (the "Company" or "Charlotte's Web"), a botanical wellness innovation company and the market ...
Charlotte's Web Commends Representative Griffith for Leadership Introducing Hemp Enforcement, Modernization, and Protection (HEMP) Act
HEMP Act Establishes FDA Oversight, Manufacturing Standards, and Consumer Safety Requirements While Preserving Legal Market for Compliant CBD Products LOUISVILLE, Colo., Jan. 23, 2026 /PRNewswire/ - (...
Presidential Executive Order Validates DeFloria's Strategy in Pharmaceutical Cannabinoid Drug Development
DeFloria Advancing Charlotte's Web Legacy as Pioneer in Cannabinoid Health, with Phase 2 Clinical Trials for Autism Botanical Drug LOUISVILLE, Colo. and WASHINGTON , Dec. 19, 2025 /PRNewswire/ - DeFlo...
Charlotte's Web Serves as a Premier CBD Partner for Landmark Medicare and Medicaid Pilot Program
Pilot Program Expands Access to Science-Backed CBD for Senior Cancer Patients through Healthcare Insurance Coverage LOUISVILLE, Colo. , Dec. 18, 2025 /PRNewswire/ - (TSX: CWEB) (OTCQB: CWBHF) Charlott...
Charlotte's Web Reports Q3 2025 Results
Healthcare Focus, Product Innovation, and Cost Improvements LOUISVILLE, Colo. , Nov. 12, 2025 /PRNewswire/ - (TSX: CWEB) (OTC: CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company...
Charlotte's Web Appoints M. Borgia Walker to Board of Directors
Accomplished Executive Brings Three Decades of Transformation and Financial Leadership Experience from Global Consumer Goods and Financial Services Industries LOUISVILLE, Colo. , Oct. 21, 2025 /PRNews...
Charlotte's Web™ Expands its Brightside Line with Launch of Knockout Hemp THC Sleep Gummies
The fourth addition to its hemp-derived THC product lineup, Knockout expands Charlotte's Web's Brightside collection into the sleep market by combining cannabinoids, clean ingredients, and fast-acti...
Charlotte's Web™ Expands Sleep Category with Launch of Quiet Sleep Mushroom Gummies
A new survey shows that 43% of Americans have difficulty falling asleep because they can't quiet their minds; new Melatonin-free and CBD-free sleep support utilizes reishi mushroom, chamomile, and mag...
Charlotte's Web Announces Plans to Establish a Scientific Advisory Board
Scientific Advisory Board to Strengthen Medical Channel Strategy and Accelerate R&D Initiatives LOUISVILLE, Colo. , Sept. 4, 2025 /PRNewswire/ - (TSX: CWEB) (OTCQB: CWBHF) Charlotte's Web Holdings, In...
Charlotte's Web Holdings Earnings Call Transcript: Q2 2025
Q2 saw 4.2% year-over-year revenue growth, margin improvement, and a 43% reduction in net loss. Cost savings and in-house manufacturing are expected to drive positive cash flow by 2026, with new product launches and omnichannel expansion fueling momentum.
Charlotte's Web Reports Year-Over-Year Growth For Q2 2025
Second Consecutive Quarter of Year-over-Year Revenue Growth Supported by New Product Innovations and Omnichannel Expansion LOUISVILLE, Colo. , Aug. 13, 2025 /PRNewswire/ - (TSX: CWEB) (OTC: CWBHF), C...
Charlotte's Web 2025 Second Quarter Earnings Call and Webcast Notice
LOUISVILLE, Colo. , Aug. 5, 2025 /PRNewswire/ - (TSX: CWEB) (OTC: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte ' s Web" or the "Company") a botanical wellness innovation company and the market le...
Charlotte's Web Reports Shareholder Meeting Voting Results
LOUISEVILLE, Colo., June 13, 2025 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte ' s Web" or the "Company") is pleased to announce the results from its 2025 annua...
Charlotte's Web Reports Year-Over-Year Growth For Q1 2025
Early proof points confirm transformation strategy traction LOUISVILLE, Colo. , May 14, 2025 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Compan...
Charlotte's Web Holdings Earnings Call Transcript: Q4 2024
Consecutive quarterly revenue growth was achieved in 2024, with strong e-commerce and new product launches offsetting retail headwinds from state regulations. Cost reductions and operational efficiencies led to improved margins and a positive Q4 adjusted EBITDA, positioning the company for year-over-year growth and margin expansion in 2025.
Charlotte's Web Reports 2024 Fourth Quarter and Year-End Financial Results
2024 Delivered Quarterly Growth and Large Scale Cost Optimization LOUISVILLE, Colo. , March 19, 2025 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web"...
Charlotte's Web 2024 Fourth Quarter Earnings Call and Webcast Notice
LOUISVILLE, Colo. , Feb. 25, 2025 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte ' s Web" or the "Company") the market leader in cannabidiol (CBD) hemp extract we...
Charlotte's Web Announces DeFloria to enter Phase 2 FDA Clinical Trial for Autism Spectrum Disorder Treatment
LOUISVILLE, Colo., Feb. 24, 2025 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), a market leader in hemp extract wellness products, is pl...
DeFloria Receives Investigational New Drug Application Clearance from FDA for Phase 2 Clinical Trial of AJA001, an Oral Cannabinoid Drug Being Developed for the Treatment of Autism Spectrum Disorder (ASD)
DeFloria plans to initiate a Phase 2 clinical trial by mid-year 2025 LITTLETON, Colo. , Feb. 24, 2025 /PRNewswire/ -- DeFloria, Inc., a collaboration between Ajna BioSciences PBC and Charlotte's Web H...
Charlotte's Web Provides Update on DeFloria's Phase 1 Results Targeting Autism Spectrum Disorder
Promising Findings Presented at the American College of Neuropsychopharmacology Annual Meeting LOUISVILLE, Colo. , Dec. 12, 2024 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, In...